The Hamilton, Ont.-based biopharmaceutical company, which aims to cure cancer through radiopharmaceuticals, filed its registration statement with the U.S. Securities and Exchange Commission on Friday. (The Globe and Mail)
The Hamilton, Ont.-based biopharmaceutical company, which aims to cure cancer through radiopharmaceuticals, filed its registration statement with the U.S. Securities and Exchange Commission on Friday. (The Globe and Mail)
The Hamilton, Ont.-based biopharmaceutical company, which aims to cure cancer through radiopharmaceuticals, filed its registration statement with the U.S. Securities and Exchange Commission on Friday. (The Globe and Mail)
Talking point: Founded in 2014, Fusion received a US$20-million investment from the Canadian Plan Investment Board in January. It’s the third Canadian biotech company to vie for a spot on the Nasdaq in the past week. On May 20, Repare Therapeutics, a St-Laurent, Québec-based oncology company, also filed for a US$100-million IPO. On June 3, Vancouver-based Chinook Therapeutics Inc., a kidney-disease drug developer, announced a merger with Silicon Valley’s Aduro Biotech, and is expected to trade under the Nasdaq symbol “KDNY.”
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.